In December 2007, the U.S. District Court of Massachusetts settled a class-action lawsuit that involved Merck Serono and the drug Serostim. The lawsuit claims that Merck Serono encouraged doctors to prescribe Serostim off-label for criteria that were not approved by the FDA. Merck Serono denies these claims and any liability. However, Merck Serono has entered into a settlement "solely to avoid the further expense, inconvenience, burden, and uncertainty of these lawsuits."
The settlement will pay consumers of Serostim who paid the full cash amount or a co-payment as part of their medical treatment.
|This hormonal preparation article is a stub. You can help Wikipedia by expanding it.|